Full text is available at the source.
Abstract
The brain/blood ratio one hour post-administration of intranasal risperidone-loaded solid lipid nanoparticles (RSLNs) was 1.36 ± 0.06, significantly higher than the ratio for risperidone solution (0.17 ± 0.05).
- RSLNs demonstrated higher hindlimb retraction time values compared to the risperidone solution, suggesting improved brain targeting.
- The pharmacokinetics study in mice indicated nearly 10-fold and 5-fold increases in brain/blood ratios for intranasal RSLNs compared to intravenous risperidone solution and intravenous RSLNs, respectively.
- Gamma scintigraphy imaging confirmed that RSLNs localized in the brain following both intravenous and intranasal administration.
- These results suggest a potential direct nose-to-brain delivery route for nanoparticles administered through the nasal cavity.
Simplified